899 related articles for article (PubMed ID: 12172980)
1. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeting of BCL2 and BCLXL proteins by synthetic BCL2 homology 3 domain peptide enhances the efficacy of chemotherapy.
Dharap SS; Chandna P; Wang Y; Khandare JJ; Qiu B; Stein S; Minko T
J Pharmacol Exp Ther; 2006 Mar; 316(3):992-8. PubMed ID: 16291730
[TBL] [Abstract][Full Text] [Related]
4. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
Goldwasser F; Bae I; Fornace AJ; Pommier Y
Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
6. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides.
Dharap SS; Qiu B; Williams GC; Sinko P; Stein S; Minko T
J Control Release; 2003 Aug; 91(1-2):61-73. PubMed ID: 12932638
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
Hentze H; Latta M; Künstle G; Dhakshinamoorthy S; Ng PY; Porter AG; Wendel A
Hepatology; 2004 May; 39(5):1311-20. PubMed ID: 15122760
[TBL] [Abstract][Full Text] [Related]
9. Targeted proapoptotic anticancer drug delivery system.
Chandna P; Saad M; Wang Y; Ber E; Khandare J; Vetcher AA; Soldatenkov VA; Minko T
Mol Pharm; 2007; 4(5):668-78. PubMed ID: 17685579
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of camptothecin and polymer-conjugated camptothecin in tumor spheroids and solid tumors.
Ying V; Haverstick K; Page RL; Saltzman WM
J Biomater Sci Polym Ed; 2007; 18(10):1283-99. PubMed ID: 17939886
[TBL] [Abstract][Full Text] [Related]
11. Bcl-xL modulates apoptosis induced by anticancer drugs and delays DEVDase and DNA fragmentation-promoting activities.
Schmitt E; Cimoli G; Steyaert A; Bertrand R
Exp Cell Res; 1998 Apr; 240(1):107-21. PubMed ID: 9570926
[TBL] [Abstract][Full Text] [Related]
12. [Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines].
Yang XK; Xing H; Zheng F; Gao QL; Wang W; Lu YP; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):158-61. PubMed ID: 12816691
[TBL] [Abstract][Full Text] [Related]
13. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
Frankel A; Man S; Elliott P; Adams J; Kerbel RS
Clin Cancer Res; 2000 Sep; 6(9):3719-28. PubMed ID: 10999766
[TBL] [Abstract][Full Text] [Related]
14. Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation.
Paranjpe PV; Chen Y; Kholodovych V; Welsh W; Stein S; Sinko PJ
J Control Release; 2004 Nov; 100(2):275-92. PubMed ID: 15544875
[TBL] [Abstract][Full Text] [Related]
15. In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-camptothecin conjugates to the rat brain.
Fleming AB; Haverstick K; Saltzman WM
Bioconjug Chem; 2004; 15(6):1364-75. PubMed ID: 15546204
[TBL] [Abstract][Full Text] [Related]
16. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line.
Wu GS; Ding Z
Oncogene; 2002 Jan; 21(1):1-8. PubMed ID: 11791171
[TBL] [Abstract][Full Text] [Related]
17. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.
Gupta M; Fan S; Zhan Q; Kohn KW; O'Connor PM; Pommier Y
Clin Cancer Res; 1997 Sep; 3(9):1653-60. PubMed ID: 9815856
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents.
Zanon M; Piris A; Bersani I; Vegetti C; Molla A; Scarito A; Anichini A
Cancer Res; 2004 Oct; 64(20):7386-94. PubMed ID: 15492260
[TBL] [Abstract][Full Text] [Related]
20. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]